irinotecan has been researched along with Angiogenesis, Pathologic in 58 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (3.45) | 18.2507 |
2000's | 24 (41.38) | 29.6817 |
2010's | 30 (51.72) | 24.3611 |
2020's | 2 (3.45) | 2.80 |
Authors | Studies |
---|---|
Dannhardt, G; Ganser, C; Kindler, T; Kramb, JP; Lauermann, E; Maderer, A; Moehler, M; Plutizki, S; Stauder, T | 1 |
Chen, TL; Hou, MH; Jain, V; Kuppusamy, R; Lee, TC; Lin, YW; Patel, AS; Su, TL | 1 |
Ahn, JH; Chun, KH; Ha, E; Kang, HG; Kim, D; Kim, DH; Kim, SJ; Lee, HW; Lee, S; Lee, SH; Park, HW; Yoem, DH; You, WK | 1 |
Kralova, V; Krbal, L; Matouskova, P; Rudolf, E; Skarkova, V; Soukup, J | 1 |
Esna-Ashari, O; Fathi-Azarbayjani, A; Kheradmand, F; Malekinejad, H; Mohammadian, M; Rasmi, Y; Zeynali-Moghaddam, S | 1 |
Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H | 1 |
Assenat, E; Cassinotto, C; Kellil, T; Leon, P; Navarro, F; Panaro, F; Piardi, T; Rosso, E; Sega, V; Souche, R; Vendrell, J | 1 |
Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
Arao, T; Hamaguchi, T; Hayashi, H; Hirashima, Y; Honma, Y; Horita, Y; Iwasa, S; Kato, K; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Okita, NT; Shimada, Y; Takashima, A; Togashi, Y; Yamada, Y | 1 |
Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
André, T; Bennouna, J; Borg, C; Bouché, O; Jary, M; Kim, S | 1 |
Canon, JL; Carrasco, J; Chapaux, X; Danse, E; Gigot, JF; Gizzi, M; Hubert, C; Humblet, Y; Jouret-Mourin, A; Lannoy, V; Lefesvre, P; Navez, B; Pairet, G; Sempoux, C; Tinton, N; Van den Eynde, M | 1 |
Delestre, L; Dewitte, A; Lansiaux, A; Lepretre, F; Pham, MH; Wattez, N | 1 |
Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT | 1 |
Bawa, O; Bosq, J; Daudigeos-Dubus, E; Geoerger, B; Lanvers-Kaminsky, C; Le Dret, L; Opolon, P; Pagès, M; Vassal, G; Vievard, A; Villa, I; Zopf, D | 1 |
Akagi, Y; Ishibashi, N; Mizobe, T; Mori, S; Murakami, H; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
Adam, MJ; Anantha, M; Baker, JH; Bally, MB; Co, SJ; Dragowska, WH; Kozlowski, P; Kyle, AH; Lam, J; Minchinton, AI; Ng, SS; Oliver, T; Ramsay, E; Ruth, TJ; Sy, J; Yapp, DT; Yung, A | 1 |
Dehais, C; Laigle-Donadey, F; Mazeron, JJ; Sanson, M | 1 |
Axelrod, F; Basi, J; Clarke, MF; Donigian, L; Dylla, S; Fitch-Bruhns, M; Gurney, A; Hoey, T; Lazetic, S; Lewicki, J; Park, IK; Sato, A; Satyal, S; Wang, X; Yen, WC | 1 |
Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P | 1 |
Ishikawa, E; Kamiyama, H; Mashiko, R; Matsumura, A; Osuka, S; Takano, S | 1 |
Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P | 1 |
Broholm, H; Christensen, IJ; Eriksen, JG; Grunnet, K; Hasselbalch, B; Horsman, MR; Lassen, U; Poulsen, HS; Stockhausen, MT | 1 |
Becherini, P; Cilli, M; Emionite, L; Greenberger, LM; Horak, ID; Loi, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P | 1 |
Choijamts, B; Emoto, M; Kawarabayashi, T; Miyamoto, S; Naganuma, Y; Nakajima, K; Tachibana, K | 1 |
Chayama, K; Kitadai, Y; Kodama, M; Ohara, E; Ohnishi, M; Shinagawa, K; Sumida, T; Tanaka, M; Tanaka, S; Yasui, W | 1 |
Alì, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Di Paolo, A; Fioravanti, A; Fontanini, G; Orlandi, P | 1 |
Dumble, M; Greenberger, LM; Horak, ID; Kraft, P; Mehlig, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P; Wang, M | 1 |
Burden, RE; Gazdoiu, M; Gormley, JA; Jaquin, TJ; Johnston, JA; Kuehn, D; Kwok, HF; McClurg, A; Olwill, SA; Scott, CJ; Ward, C | 1 |
Lewis, MR | 1 |
Bachellier, P; Gaub, MP; Guenot, D; Guérin, E; Larsen, AK; Maier, A; Moras, D; Neuville, A; Oudet, P; Pencreach, E; Petitprez, A; Poch, O; Raffelsberger, W; Rohr, S; Schneider, A | 1 |
Pauwels, P; Peeters, M; Reutelingsperger, CP; Staelens, S; Van Damme, N; Van de Wiele, C; Vangestel, C | 1 |
Akama, TO; Bobkov, AA; Fukuda, M; Fukuda, MN; Hatakeyama, S; Nakayama, J; Ohyama, C; Shibata, TK; Sugihara, K; Takano, Y; Tamura, N; Wong, SM | 1 |
Albertsson, P; Lennernäs, B; Norrby, K | 1 |
Addeo, P; Bachellier, P; Chenard, MP; Fuchshuber, P; Jaeck, D; Narita, M; Oussoultzoglou, E; Rather, M; Rosso, E | 1 |
Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isıkdogan, A; Kaplan, MA; Ozkan, M; Ozturk, SC | 1 |
Cha, H; Cho, WJ; Lee, HY; Lee, JC; Lee, SJ; Lee, YH; Min, YJ; Moon, CH; Park, HJ; Park, JW; Seo, J; Song, HT | 1 |
Berlin, JD | 1 |
Akbulut, H; Akbulut, KG; Altuntas, F; Cindoruk, M; Icli, F; Ozturk, G; Unal, E | 1 |
Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M | 1 |
Chu, E | 1 |
Vanhoefer, U | 1 |
Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W | 1 |
El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V | 1 |
Abbruzzese, JL; Eng, C | 1 |
Bucana, CD; Carter, KB; Jasser, SA; Kim, S; Myers, JN; Wang, Z; Yazici, YD | 1 |
Calvet, L; Elie, N; Geoerger, B; Joseph, JM; Machet, L; Morizet, J; Opolon, P; Regairaz, M; Vassal, G | 1 |
Battistoni, F; Di Cuonzo, G; Gavasci, M; Gebbia, N; Rocci, L; Russo, A; Santini, D; Silletta, M; Tonini, G; Vincenzi, B | 1 |
Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Frank, C; Hapke, G; Li, ZR; Rustum, YM; Tóth, K; Yin, MB | 1 |
Fuchs, CS; Goldberg, RM; Hurwitz, HI | 1 |
Brem, S; Wong, ET | 1 |
Meric, JB | 1 |
Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY | 1 |
Cao, Y; Desjardins, A; Dewhirst, MW; Friedman, HS; Herndon, JE; Marcello, JE; McLendon, RE; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
Cunningham, D; Jackson, C | 1 |
Ishibashi, M; Kaneko, M; Kaneko, S | 1 |
Chuang, N; Cohen, HW; O'Leary, JJ; Potmesil, M; Ren, CJ; Shapiro, RL | 1 |
Burton, E; Prados, M | 1 |
12 review(s) available for irinotecan and Angiogenesis, Pathologic
Article | Year |
---|---|
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Progression-Free Survival; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2018 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2015 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Irinotecan; Neovascularization, Pathologic; Temozolomide; Vascular Endothelial Growth Factor A | 2009 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fluorouracil; Humans; Indoles; Irinotecan; Leucovorin; Male; Neovascularization, Pathologic; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2002 |
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Neovascularization, Pathologic; Predictive Value of Tests; Prognosis; Survival Analysis | 2003 |
[Novel molecular approaches in the therapy of advanced colorectal carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neoplasm Staging; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2003 |
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Drug Delivery Systems; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2004 |
The role of targeted therapy in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Epidermal Growth Factor; Humans; Irinotecan; Neovascularization, Pathologic; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2007 |
Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2008 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Irinotecan; Neovascularization, Pathologic; Oligodendroglioma; Protease Inhibitors; Signal Transduction; Temozolomide; Thalidomide | 1999 |
3 trial(s) available for irinotecan and Angiogenesis, Pathologic
Article | Year |
---|---|
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Choline; Creatine; Dacarbazine; Feasibility Studies; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Thrombospondins; Vascular Endothelial Growth Factor A | 2007 |
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Female; Humans; Hypoxia; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Proportional Hazards Models; Radiography; Retrospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
43 other study(ies) available for irinotecan and Angiogenesis, Pathologic
Article | Year |
---|---|
Novel 3-Azaindolyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cells, Cultured; Chick Embryo; fms-Like Tyrosine Kinase 3; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Growth Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Maleimides; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Design; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Squamous Cell; Neovascularization, Pathologic; Phthalazines; Small Cell Lung Carcinoma; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Calcium-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Female; Humans; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Pyrazoles; Signal Transduction; Stomach Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |
Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Irinotecan; Lymphatic Metastasis; Neoplasm Invasiveness; Neovascularization, Pathologic; Oxaliplatin | 2018 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Lactams, Macrocyclic; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Microvessels; Neovascularization, Pathologic; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies | 2019 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Survival Rate | 2014 |
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2015 |
Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Cetuximab; Colonic Neoplasms; Drug Synergism; Flow Cytometry; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylation; Signal Transduction | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Compounding; Glioblastoma; Humans; Irinotecan; Liposomes; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Drug Screening Assays, Antitumor; Female; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines | 2015 |
Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Camptothecin; Cell Proliferation; Chemotherapy, Adjuvant; Colonic Neoplasms; Humans; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Neovascularization, Pathologic; Postoperative Care; Rats; Rats, Inbred F344; Rats, Nude; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Hypoxia; Doxorubicin; Fluorouracil; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Irinotecan; Liposomes; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Nanocapsules; Neoplasms, Experimental; Neovascularization, Pathologic; Tissue Distribution; Xenograft Model Antitumor Assays | 2008 |
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Calcium-Binding Proteins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chaperonin 60; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Membrane Proteins; Mice; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Receptors, Notch; Secondary Prevention; Xenograft Model Antitumor Assays | 2009 |
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line; Cell Proliferation; Colorectal Neoplasms; Drug Administration Schedule; Endothelial Cells; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Microvessels; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2009 |
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Proliferation; Glioma; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Brain Neoplasms; Camptothecin; Cell Hypoxia; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prospective Studies | 2010 |
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Neuroblastoma; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors | 2010 |
Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Drug Administration Schedule; Female; Flow Cytometry; Humans; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Sarcoma; Ultrasonic Therapy; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Camptothecin; Cell Proliferation; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Male; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neovascularization, Pathologic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Blotting, Western; Camptothecin; Cation Transport Proteins; Cell Proliferation; Cells, Cultured; Copper-Transporting ATPases; Drug Synergism; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Indazoles; Irinotecan; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thrombospondins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2011 |
Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathepsins; Cell Line, Tumor; Colon; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; Gene Expression; Humans; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Looking through the vascular normalization window: timing antiangiogenic treatment and chemotherapy with (99m)Tc-annexin A5.
Topics: Animals; Annexin A5; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Irinotecan; Neovascularization, Pathologic; Organotechnetium Compounds; Tomography, Emission-Computed, Single-Photon | 2011 |
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2012 |
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Topics: Actins; Angiopoietin-1; Animals; Annexin A5; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Camptothecin; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Transformation, Neoplastic; Colorectal Neoplasms; Female; Irinotecan; Mice; Microvessels; Neovascularization, Pathologic; Organotechnetium Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Tomography, Emission-Computed, Single-Photon; Transcription, Genetic; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
Topics: Amino Acid Sequence; Animals; Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbohydrates; Cell Line, Tumor; Drug Delivery Systems; HCT116 Cells; Humans; Hydrazines; Injections, Intravenous; Irinotecan; Luminescent Measurements; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Mimicry; Molecular Sequence Data; Neoplasms; Neovascularization, Pathologic; Peptides; Protein Binding; Xenograft Model Antitumor Assays | 2011 |
Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.
Topics: Animals; Body Weight; Camptothecin; Endothelial Cells; Irinotecan; Male; Mesentery; Mitoxantrone; Neovascularization, Pathologic; Neovascularization, Physiologic; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Topoisomerase Inhibitors; Vascular Endothelial Growth Factor A | 2012 |
Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Indocyanine Green; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Prognosis; Risk Factors; Survival Rate | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Sodium Compounds; Telomere | 2013 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Fluorouracil; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Life Tables; Lymphokines; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Nitrates; Nitric Oxide; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Validation of the role of angiogenesis as a chemotherapeutic target.
Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Fluorouracil; Humans; Irinotecan; Leucovorin; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Survival Analysis; Wound Healing | 2003 |
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Fluorouracil; HT29 Cells; Humans; Ibuprofen; Irinotecan; Lactones; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Sulfones; Survival Analysis; Xenograft Model Antitumor Assays | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Female; Fluorouracil; Galanin; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Leucovorin; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Octreotide; Organoplatinum Compounds; Oxaliplatin; Platelet Endothelial Cell Adhesion Molecule-1; Poly(ADP-ribose) Polymerases; Serotonin; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Therapy, Combination; Follow-Up Studies; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Tongue Neoplasms; Treatment Outcome | 2005 |
Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
Topics: Animals; Camptothecin; Carrier Proteins; Child, Preschool; Cytokines; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation; Humans; Irinotecan; Male; Mice; Neovascularization, Pathologic; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Interferon-gamma; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiog
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cysteine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Organoselenium Compounds; Selenocysteine; Transplantation, Heterologous | 2006 |
Taming glioblastoma: targeting angiogenesis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Survival Rate | 2007 |
Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Immunoenzyme Techniques; Infant; Irinotecan; Male; Mice; Neovascularization, Pathologic; Neuroblastoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cornea; Disease Models, Animal; Fibroblast Growth Factor 2; Irinotecan; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Neovascularization, Physiologic; Topotecan; Vincristine | 1999 |